Abstract CT022: A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors

MLA

Sanjeev Kumar, et al. “Abstract CT022: A Phase Ib Study of Wee1 Inhibitor Adavosertib in Patients with Advanced Solid Tumors.” Cancer Research, vol. 79, July 2019, p. CT022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........45b405c601fcdb4ea456f5f337892d4a&authtype=sso&custid=ns315887.

APA

Sanjeev Kumar, Esteban Rodrigo Imedio, Jasgit C. Sachdev, Juliann Chmielecki, Ganesh Mugundu, Gerald Steven Falchook, David R. Spigel, Melissa Lynne Johnson, & Suzanne F. Jones. (2019). Abstract CT022: A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors. Cancer Research, 79, CT022.

Chicago

Sanjeev Kumar, Esteban Rodrigo Imedio, Jasgit C. Sachdev, Juliann Chmielecki, Ganesh Mugundu, Gerald Steven Falchook, David R. Spigel, Melissa Lynne Johnson, and Suzanne F. Jones. 2019. “Abstract CT022: A Phase Ib Study of Wee1 Inhibitor Adavosertib in Patients with Advanced Solid Tumors.” Cancer Research 79 (July): CT022. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........45b405c601fcdb4ea456f5f337892d4a&authtype=sso&custid=ns315887.